**FOI Ref: 6379**

**Category(ies): Clinical - Drugs**

**Subject: Biologic and Biosimilar Products within Rheumatology**

**Date Received: 05/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Q1. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:   * Abatacept [Orencia] * Adalimumab [Humira] * Adalimumab Biosimilars * Apremilast [Otezla] * Baricitinib [Olumiant] * Certolizumab [Cimzia] * Etanercept [Enbrel] * Etanercept Biosimilars * Filgotinib [Jyseleca] * Golimumab [Simponi] * Guselkumab [Tremfya] * Infliximab [Remicade] * Infliximab Biosimilars * Ixekizumab [Taltz] * Risankizumab [Skyrizi] * Rituximab [MabThera] * Rituximab Biosimilars * Sarilumab [Kevzara] * Secukinumab [Cosentyx] * Tocilizumab [Ro Actemra] * Tofacitinib [Xeljanz] * Upadacitinib [Rinvoq] * Ustekinumab [Stelara] | * Abatacept [Orencia] - 32 * Adalimumab [Humira] - 0 * Adalimumab Biosimilars - 0 * Amgevita (Adalimumab) - 130 * Apremilast [Otezla] - 0 * Baricitinib [Olumiant] - 12 * Benepali - 340 * Certolizumab [Cimzia] - 13 * Etanercept [Enbrel] - 6 * Etanercept Biosimilars - 0 * Filgotinib [Jyseleca] - 0 * Golimumab [Simponi] - 10 * Guselkumab [Tremfya] - 0 * Infliximab [Remicade] - 0 * Infliximab Biosimilars - 0 * Ixekizumab [Taltz] - 0 * Metoject – 333 * Risankizumab [Skyrizi] - 0 * Rituximab [MabThera] - 0 * Rituximab Biosimilars - 0 * Sarilumab [Kevzara] - 0 * Secukinumab [Cosentyx] - 19 * Tocilizumab [Ro Actemra] - 34 * Tofacitinib [Xeljanz] - 0 * Upadacitinib [Rinvoq] - 0 * Ustekinumab [Stelara] - 0 |
| Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.   * Abatacept [Orencia] * Adalimumab [Humira] * Adalimumab Biosimilars * Apremilast [Otezla] * Certolizumab [Cimzia] * Etanercept [Enbrel] * Etanercept Biosimilars * Golimumab [Simponi] * Guselkumab [Tremfya] * Infliximab [Remicade] * Infliximab Biosimilars * Ixekizumab [Taltz] * Risankizumab [Skyrizi] * Secukinumab [Cosentyx] * Tofacitinib [Xeljanz] * Upadacitinib [Rinvoq] * Ustekinumab [Stelara] | We are unable to provide this level of detail as we do not have a clinical data base search function on the Trust EPR system and it would *exceed the appropriate time/cost limit under Section 12(1) of the FOI Act* to manually search. |